US 340B State-Level Protections and Copay Accumulator Battles
Key Questions
What was the outcome of Novartis' challenge to Missouri's 340B contract pharmacy law?
A federal appeals court upheld Missouri's unlimited 340B contract pharmacy law, rejecting Novartis' challenge. This decision reinforces state-level intervention in 340B distribution and protects contract pharmacy arrangements.
What are copay accumulator tactics and why are they facing scrutiny?
Copay accumulator tactics involve insurers such as Oscar Health retaining manufacturer coupons, like those from Amgen, rather than crediting them toward patient deductibles. These practices are under review at both state and federal levels due to their potential effects on patient access.
How do the 340B and copay accumulator developments impact pharmaceutical strategies?
These issues affect patient access to medications and require adjustments to market access strategies in the US. Ongoing state and federal actions signal continued regulatory attention to 340B protections and copay programs.
A federal appeals court upheld Missouri's unlimited 340B contract pharmacy law, rejecting Novartis' challenge, reinforcing state-level intervention in 340B distribution. Separately, copay accumulator tactics (e.g., Oscar Health pocketing Amgen's coupon) are under scrutiny, with potential state and federal action. These issues affect patient access and market access strategy in the US.